CLChristophe Lançon

Christophe Lançon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christophe Lançon has a total of 235 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical profiles, treatment adherence, and quality of life in patients with severe mental disorders treated with cyamemazine: A real-world observational study

    by Mélanie Faugère, Vincent Achour, Eloïse Maakaron, Pierre Verney, Jade Obadia, Christelle Andrieu-Haller, Antoine Lefrere, Michel Cermolacce, Guillaume Fond, Christophe Lançon, et al.

  • Open Access

    Impact of perceived side-effects of psychotropic treatments on quality of life in patients with severe mental illness

    by Théo Korchia, Mélanie Faugère, Vincent Achour, Eloïse Maakaron, Christelle Andrieu-Haller, Guillaume Fond, Christophe Lançon

    Psychotropic medications are critical in managing severe mental illnesses (SMI) such as schizophrenia, major depressive disorder (MDD) and bipolar disorder. However, these treatments often lead to adverse side effects that can impair patients' quality of life (QoL) and affect treatment adherence. This study aims to investigate the specific side effects of psychotropic treatments that contribute to a decline in QoL among patients with SMI, independently of treatment adherence. We conducted a cross-sectional study with 1248 patients diagnosed with SMI, recruited from a university psychiatric unit in Marseille, France. QoL was assessed using the Schizophrenia Quality of Life Scale (SQoL-18), and side effects were measured using the UKU Side Effect Rating Scale. Treatment adherence was evaluated using the Medication Adherence Rating Scale (MARS). Statistical analyses included Pearson correlations and multiple linear regression models to identify predictors of QoL. The study found that side effects, as identified by the UKU scores, could significantly predict a reduction in QoL across multiple domains, including multiple dimensions of QoL and the overall QoL index, independent of treatment adherence. Patients on antipsychotics and benzodiazepines reported higher levels of adverse side effects, which correlated with lower QoL scores. An increase in the number of psychotropic treatment classes was also associated with a significant decline in QoL (p < 0.001). Managing psychic side effects and minimising polypharmacy are critical to improving QoL in patients with SMI. Clinicians should consider these factors when developing personalised treatment strategies to enhance patient outcomes.


  • Open Access

    Treatment resistant depression: A case of Muenke syndrome

    by Mélanie Faugere, Michel Cermolacce, Raphaëlle Richieri, Christophe Lançon


  • Open Access

    Psychometric Assessment of an Item Bank for Adaptive Testing on Patient-Reported Experience of Care Environment for Severe Mental Illness: Validation Study

    by Sara Fernandes, Yann Brousse, Xavier Zendjidjian, Delphine Cano, Jérémie Riedberger, Pierre-Michel Llorca, Ludovic Samalin, Daniel Dassa, Christian Trichard, Vincent Laprevote, et al.

    Background: The care environment significantly influences the experiences of patients with severe mental illness and the quality of their care. While a welcoming and stimulating environment enhances patient satisfaction and health outcomes, psychiatric facilities often prioritize staff workflow over patient needs. Addressing these challenges is crucial to improving patient experiences and outcomes in mental health care. Objective: This study is part of the Patient-Reported Experience Measure for Improving Quality of Care in Mental Health (PREMIUM) project and aims to establish an item bank (PREMIUM-CE) and to develop computerized adaptive tests (CATs) to measure the experience of the care environment of adult patients with schizophrenia, bipolar disorder, or major depressive disorder. Methods: We performed psychometric analyses including assessments of item response theory (IRT) model assumptions, IRT model fit, differential item functioning (DIF), item bank validity, and CAT simulations. Results: In this multicenter cross-sectional study, 498 patients were recruited from outpatient and inpatient settings. The final PREMIUM-CE 13-item bank was sufficiently unidimensional (root mean square error of approximation=0.082, 95% CI 0.067-0.097; comparative fit index=0.974; Tucker-Lewis index=0.968) and showed an adequate fit to the IRT model (infit mean square statistic ranging between 0.7 and 1.0). DIF analysis revealed no item biases according to gender, health care settings, diagnosis, or mode of study participation. PREMIUM-CE scores correlated strongly with satisfaction measures (r=0.69-0.78; P<.001) and weakly with quality-of-life measures (r=0.11-0.21; P<.001). CAT simulations showed a strong correlation (r=0.98) between CAT scores and those of the full item bank, and around 79.5% (396/498) of the participants obtained a reliable score with the administration of an average of 7 items. Conclusions: The PREMIUM-CE item bank and its CAT version have shown excellent psychometric properties, making them reliable measures for evaluating the patient experience of the care environment among adults with severe mental illness in both outpatient and inpatient settings. These measures are a valuable addition to the existing landscape of patient experience assessment, capturing what truly matters to patients and enhancing the understanding of their care experiences. Trial Registration: ClinicalTrials.gov NCT02491866; https://clinicaltrials.gov/study/NCT02491866

  • The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry

    by G. Fond, M. Masson, R. Richieri, T. Korchia, D. Etchecopar-Etchart, P.-L. Sunhary de Verville, C. Lançon, L. Boyer


  • Psychiatrie et réchauffement climatique

    by G. Fond, M. Masson, C. Lançon, P. Auquier, L. Boyer


  • Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia

    by Ophélia Godin, Marion Leboyer, Frank Schürhoff, Pierre-Michel Llorca, Laurent Boyer, Myrtille Andre, Meja Andrianarisoa, Bruno Aouizerate, Fabrice Berna, Delphine Capdevielle, et al.

    From The Journal of Clinical Psychiatry: Cardiovascular diseases are the primary cause of mortality in individuals with schizophrenia, yet no study has yet explored the impact of metabolic syndrome on schizophrenia relapse. This study explored the effect that several risk factors—including metabolic syndrome—have on schizophrenia relapse.


  • Auteurs

    by Amal Abdel-Baki, Isabelle Amado, Sophie Arfeuillère, Ingrid Arnaud, Maïté Arthur, Marie-Noëlle Babinet, Nadine Bazin, Tanja Bellier-Teichmann, Corinne Bismuth, Fabienne Blain-Pierre, et al.

  • Quelle définition pour la dépression résistante ?

    by Jérôme Holtzmann, Raphaëlle Richieri, Ghassen Saba, Najib Allaïli, Rémy Bation, Fanny Moliere, Isabel Nieto, Frank Bellivier, Djamila Bennabi, Maxime Bubrovszky, et al.


  • Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies

    by Pierre-Michel Llorca, Christophe Lançon, Mélanie Brignone, Benoît Rive, Samir Salah, Larry Ereshefsky, Clément Francois

    Vortioxetine is an antidepressant with multimodal activity which has shown efficacy in major depressive disorder (MDD) patients in six of ten short-term, randomized, placebo-controlled trials (completed end 2012). We performed meta-regression analyses to indirectly compare vortioxetine to seven marketed antidepressants with different mechanisms of action. To ensure study comparability, only experimental drug and placebo arms from placebo-controlled registration studies were included in primary analyses. The main outcomes were efficacy (standardized mean difference in change from baseline to 2 months on primary endpoint [MADRS/HAM-D]), and tolerability (withdrawal rate due to adverse events). For efficacy, estimates of treatment effect (negative estimates favor vortioxetine) for vortioxetine versus comparators were: agomelatine, -0.16 (p = 0.11); desvenlafaxine, 0.03 (p = 0.80); duloxetine, 0.09 (p = 0.42); escitalopram, -0.05 (p = 0.70); sertraline, -0.04 (p = 0.83); venlafaxine IR/XR, 0.12 (p = 0.33); and vilazodone, -0.25 (p = 0.11). For tolerability, all but one combination was numerically in favor of vortioxetine (odds ratio < 1), although not all differences were statistically significant: agomelatine, 1.77 (p = 0.03); desvenlafaxine, 0.58 (p = 0.04); duloxetine, 0.75 (p = 0.26); escitalopram, 0.67 (p = 0.28); sertraline, 0.30 (p = 0.01); venlafaxine, 0.47 (p = 0.01); and vilazodone, 0.64 (p = 0.18). Sensitivity analyses did not significantly alter antidepressant effect estimates or relative ranking. These meta-regression data show that vortioxetine offers a comparable or favorable combination of efficacy (measured by MADRS/HAM-D) and tolerability (measured by withdrawal rate due to adverse events) versus other antidepressants in registration studies in MDD. Alternative methods like mixed-treatment comparison and inclusion of all randomized studies and active reference arms may provide complementary information to this analysis (more evidence but also more heterogeneity). Key messages: Indirect comparisons based on registration studies allow a useful comparison between a recently approved antidepressant and an approved drug. Vortioxetine offers a comparable or favorable combination of efficacy (measured by MADRS/HAM-D assessments) and tolerability (measured by withdrawal rate due to adverse events) versus other antidepressants in registration studies in MDD.